Effect of thalidomide on colorectal cancer liver metastases in CBA mice

Journal of Surgical Oncology

Volumn 91, Issue 2, 2005, Pages 134-140

  Daruwalla, Jurstine ^a,b   Nikfarjam, Mehrdad ^a   Malcontenti Wilson, Cathy ^a   Muralidharan, Vijayaragavan ^a   Christophi, Chris ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Angiogenesis; Colorectal cancer; Liver metastases; Thalidomide

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; DIMETHYLHYDRAZINE; THALIDOMIDE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; LASER DOPPLER FLOWMETRY; LIVER METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; STEREOMETRY; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANIMALS; COLORECTAL NEOPLASMS; FIBROBLAST GROWTH FACTOR 2; IMMUNOHISTOCHEMISTRY; LASER-DOPPLER FLOWMETRY; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED CBA; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23044438382     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20289     Document Type: Article

References (28)

1. Labianca R, Pessi MA, Zamparelli G: Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy. Drugs 1997;53:593-607.
2. Fine HA, Figg WD, Jaeckle K, et al.: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18:708-715.
3. Eckhardt SG: Angiogenesis inhibitors as cancer therapy. Hosp Pract 1999;34:63-68, 77-69, 83-84.
4. Konno H, Tanaka T, Baba M, et al.: Antiangiogenic therapy for liver metastasis of gastrointestinal malignancies. J Hepatobiliary Pancreat Surg 1999;6:1-6.
5. Eisen T, Boshoff C, Mak I, et al.: Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000;82:812-817.
6. Singhal S, Mehta J: Thalidomide in cancer. Biomed Pharmacother 2002;56:4-12.
7. Raje N, Anderson KC: Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol 2002;14:635-640.
8. Tseng JE, Glisson BS, Khuri FR, et al.: Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2001;92: 2364-2373.
9. Ng SS, Brown M, Figg WD: Thalidomide, an antiangiogenic agent with clinical activity in cancer. Biomed Pharmacother 2002; 56:194-199.
10. D'Amato RJ, Loughnan MS, Flynn E, et al.: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91: 4082-4085.
11. Kuruppu D, Christophi C, Maeda H, et al.: Changes in the microvascular architecture of colorectal liver metastases following the administration of SMANCS/lipiodol. J Surg Res 2002; 103:47-54.
12. Kuruppu D, Christophi C, Bertram JF, et al.: Characterization of an animal model of hepatic metastasis. J Gastroenterol Hepatol 1996;11:26-32.
13. Malcontenti-Wilson C, Muralidharan V, Skinner S, et al.: Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 2001;7:1052-1060.
14. Kuruppu D, Christophi C, O'Brien PE: Microvascular architecture of hepatic metastases in a mouse model. HPB Surg 1997;10: 149-157; discussion 158.
15. Sheskin J: The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide. Int J Dermatol 1980; 19:318-322.
16. Kumar S, Witzig TE, Rajkumar SV: Thalidomide as an anticancer agent. J Cell Mol Med 2002;6:160-174.
17. Rajkumar SV, Witzig TE: A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 2000;26:351-362.
18. Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
19. Baidas SM, Winer EP, Fleming GF, et al.: Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000;18:2710-2717.
20. Weidner N, Semple JP, Welch WR, et al.: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
21. Figg WD, Dahut W, Duray P, et al.: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888-1893.
22. Richardson P, Hideshima T, Anderson K: Thalidomide: Emerging role in cancer medicine. Annu Rev Med 2002;53:629-657.
23. Pollard M: Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats. Cancer Letters 1996;101: 21-24.
24. Kenyon BM, Browne F, D'Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-978.
25. Kotoh T, Dhar DK, Masunaga R, et al.: Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 1999;125:536-544.
26. Stephens TD, Bunde CJ, Fillmore BJ: Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 2000;59:1489-1499.
27. Bauer KS, Dixon SC, Figg WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998;55:1827-1834.
28. Moreira AL, Friedlander DR, Shif B, et al.: Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neurooncol 1999;43:109-114.